Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seema Bhat

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Leukemia|April 6, 2021
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patientsCecelia R Miller, Ying Huang, Amy S Ruppert, et al.
Blood|December 24, 2024
Non-V600E BRAF mutations and treatment for hairy cell leukemiaEvgeny Arons, Chin-Hsien Tai, Joshi Suraj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I StudyDeborah M Stephens, Ying Huang, Amy S Ruppert, et al.
JACC. Cardiooncology|November 16, 2023
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: <i>JACC: CardioOncology</i> State-of-the-Art ReviewCooper Quartermaine, Sanam M Ghazi, Aneeq Yasin, et al.
JAMA Oncology|February 2, 2023
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated CardiotoxicityBenjamin Buck, Aaron P Chum, Mitkumar Patel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Research Square|February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Leukemia|May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelinesMichael Grever, Leslie Andritsos, Versha Banerji, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Leukemia|April 6, 2021
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patientsCecelia R Miller, Ying Huang, Amy S Ruppert, et al.
Blood|December 24, 2024
Non-V600E BRAF mutations and treatment for hairy cell leukemiaEvgeny Arons, Chin-Hsien Tai, Joshi Suraj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I StudyDeborah M Stephens, Ying Huang, Amy S Ruppert, et al.
JACC. Cardiooncology|November 16, 2023
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: <i>JACC: CardioOncology</i> State-of-the-Art ReviewCooper Quartermaine, Sanam M Ghazi, Aneeq Yasin, et al.
JAMA Oncology|February 2, 2023
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated CardiotoxicityBenjamin Buck, Aaron P Chum, Mitkumar Patel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Research Square|February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Leukemia|May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelinesMichael Grever, Leslie Andritsos, Versha Banerji, et al.
Pageof 2